Adamas Pharmaceuticals Inc. (ADMS)

6.00
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 6.00
Open 6.00
Day Low/High 5.90 / 6.10
52 Wk Low/High 4.20 / 29.49
Volume 256.90K
Avg Volume 350.60K
Exchange NASDAQ
Shares Outstanding 27.53M
Market Cap 165.20M
EPS -4.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.

Playing Biotech After FDA Approval

Playing Biotech After FDA Approval

Small biotech stocks have a number of hurdles around FDA approval. Here is how to play that cycle.

Drug Approvals Don't Always Translate Into Stock Gains: 3 Biotech Examples

Drug Approvals Don't Always Translate Into Stock Gains: 3 Biotech Examples

Winning FDA approval isn't always a win.

Winning FDA Approval Isn't Always a Win

Winning FDA Approval Isn't Always a Win

The experiences of three biotechs show how drug approvals don't always translate into stock gains.

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

Hurricane Harvey, Now a Category 2, Heads for Oil-Rich Gulf Coast

Hurricane Harvey, Now a Category 2, Heads for Oil-Rich Gulf Coast

Hurricane Harvey was upgraded to a category 2 storm overnight and could be a category 3 before the day is over.

3 Biotechs to Buy This Summer

3 Biotechs to Buy This Summer

These companies will do well, despite a range bound sector.

Biotech Bargain Bin Bursts With Bounty

Biotech Bargain Bin Bursts With Bounty

This sector is one of the few areas of the market where you'll find myriad compelling values.

Fitting Finish to a Tough Year

Today's action was disappointing and frustrating.